Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 16/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYBB | P04839 | 9/20 | 0.42 |
| ▸ | NOX5 | Q96PH1 | 9/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 9/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2219788 | 0.88 | NOX4 (0.48) | NOX4ALDH1A1SMN1; SMN2CYBBNOX5 | |
| SCHEMBL2218198 | 0.85 | NOX4 (0.64) | NOX4CYBBNOX5NOX1 | |
| SCHEMBL2217732 | 0.81 | NOX4 (0.72) | NOX4CYBBNOX5NOX1 | |
| SCHEMBL2216500 | 0.81 | NOX4 (0.69) | NOX4CYBBNOX5NOX1CYP2C9 | |
| SCHEMBL2217987 | 0.80 | NOX4 (0.49) | NOX4CYBBNOX5NOX1CYP2C9 | |
| SCHEMBL2215743 | 0.77 | NOX4 (0.63) | NOX4ALDH1A1CYBBCYP2C9CYP2C19 | |
| SCHEMBL2216332 | 0.76 | NOX4 (0.44) | NOX4HTTCYBBNOX5NOX1 | |
| SCHEMBL2217927 | 0.72 | NOX4 (0.56) | NOX4CYBBNOX5NOX1 | |
| SCHEMBL2217383 | 0.72 | NOX4 (0.55) | NOX4CYBBNOX5NOX1 | |
| SCHEMBL1303163 | 0.71 | NOX4 (0.59) | NOX4SMN1; SMN2CYBBNOX5NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2674160-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-10-28 | — | — | EP | claimed |
| US-9012449-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-21 | — | — | US | claimed |
| EP-2674160-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GenKyoTex SA (CH) | 2013-12-18 | — | — | EP | claimed |
| EP-2349261-B1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2013-08-14 | — | — | EP | claimed |
| US-20130143879-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2013-06-06 | — | — | US | claimed |
| US-8455485-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-06-04 | — | — | US | claimed |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | claimed |
| EP-2674160-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-10-28 | — | — | EP | disclosed |
| EP-2674160-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-9012449-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-21 | — | — | US | disclosed |
| US-9012449-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-21 | — | — | US | disclosed |
| US-9012449-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-21 | — | — | US | disclosed |
| EP-2674160-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GenKyoTex SA (CH) | 2013-12-18 | — | — | EP | disclosed |
| US-8455485-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455485-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455485-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-06-04 | — | — | US | disclosed |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | disclosed |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | disclosed |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | disclosed |
| WO-2010035219-A2 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143879-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885ALDH1A1 230/4885LMNA 4386/4885 |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885ALDH1A1 230/4885LMNA 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.